Testosterone has a specific role in postmenopausal low desire. Understand the average benefits, clinical assessment, monitoring and safety uncertainties.
Testosterone is not a general-purpose answer to women’s low desire.
A common claim is that a low testosterone result explains reduced sexual interest and points directly to hormone treatment.
The evidence supports a more specific role for testosterone in some postmenopausal women, with clinical assessment at the center of the decision.
International consensus guidance identifies one evidence-based indication for testosterone therapy in women: appropriately assessed postmenopausal hypoactive sexual desire disorder. Often shortened to HSDD, this means low sexual desire associated with personal distress. The assessment must consider the person’s health and circumstances rather than treating reduced desire alone as a diagnosis.
That distinction gives the evidence its proper scope. The question is not whether testosterone might make women feel generally younger or more energetic. It is whether treatment may help a defined sexual concern in a group for whom evidence supports its consideration.
This is a narrower position than either “testosterone is the answer” or “testosterone has no role.” The consensus supports a clinical use without making testosterone the default response to every change in sexual interest.
The consensus reports that physiological-dose testosterone improved sexual desire compared with placebo or comparator treatment. It also reports improvements in arousal and orgasmic function. Other benefits included pleasure and responsiveness, alongside reduced sexual distress.
The average increase was approximately one additional satisfying sexual event per month over placebo or comparator treatment. That finding gives the benefit a useful scale. It describes an average across participants, not an outcome that every individual should expect.
The broader findings also matter. The reported benefit was not limited to counting sexual events. Improvements in desire and reduced distress were part of the picture, which is why a treatment discussion should identify the concern that matters to the individual.
A numerical average is useful for setting expectations. It is not a target that a person or couple needs to meet. The clinical question remains whether treatment meaningfully helps the concern for which it was considered.
The same consensus does not establish testosterone as a treatment for general wellbeing or depressed mood. It finds insufficient evidence for cognitive enhancement or prevention of cognitive decline. It also does not support testosterone as a general treatment for muscle strength or body composition, bone health or disease prevention.
These are separate claims from the evidence about postmenopausal HSDD. A benefit for a defined sexual concern does not establish a broader benefit for aging or health. Claims about vitality therefore need their own evidence rather than borrowing credibility from sexual-function research.
This distinction is useful when judging the quality of online sexual-health advice. A claim may begin with an evidence-backed use and then extend well beyond the people and outcomes studied.
The evidence leaves room for treatment to help some women. It also requires attention to the person being assessed and the conditions under which treatment is considered. Those details are not secondary to the research. They determine how closely the research fits a particular clinical decision.
The consensus calls for a biopsychosocial assessment. In plain language, this means considering physical health alongside psychological and relationship factors. Relevant contributors include psychological distress and interpersonal difficulties, as well as medication-related and other physical influences.
The guidance specifically says that testosterone levels alone cannot diagnose HSDD. A low result does not establish the diagnosis or prove that testosterone treatment is appropriate. Diagnosis follows a clinical assessment rather than a laboratory cutoff.
This distinction helps separate two questions that are often combined: what is contributing to the change in desire, and how would a proposed treatment be monitored? The first requires a broader clinical conversation. Blood testing has a different role, as discussed in this explanation of why testosterone results need context.
The consensus recommends measuring total testosterone before treatment and again three to six weeks after starting. It also describes checking serum total testosterone every six months during treatment. Clinical monitoring includes the response to treatment and signs of androgen excess, meaning unwanted effects from androgen exposure.
The guidance says treatment should stop if there is no benefit by six months. This gives reassessment a defined place in care. Treatment is not presented as something to continue indefinitely without checking whether it is helping.
The intended blood concentration is within the physiological premenopausal range. The recommendations do not apply to preparations that produce supraphysiological levels, meaning levels above that range. These are general clinical boundaries rather than instructions for choosing or adjusting an individual dose.
Formulation matters too. The consensus does not recommend oral testosterone because of adverse effects on lipid profiles. It also advises against compounded testosterone when suitable authorized alternatives are available, citing insufficient evidence for efficacy and safety.
Together, these points show why “taking testosterone” is not a complete description of care. The formulation and resulting exposure matter, as do the treatment goal and the clinician’s plan for reviewing progress.
At physiological doses, the consensus reports mild increases in acne and facial or body hair growth. These are observed treatment effects. They should be distinguished from outcomes that the available evidence has not been able to assess adequately.
Long-term safety data are unavailable beyond 24 months. The consensus also finds insufficient evidence to assess myocardial infarction, mortality and long-term breast-cancer risk. An unanswered safety question is not proof that treatment causes those harms, but it is not reassurance that the risk has been ruled out either.
The trial populations place further limits on interpretation. Women at high cardiometabolic risk were excluded from relevant trials, and most trials included women taking estrogen therapy. The consensus therefore cautions against extending cardiovascular findings to higher-risk populations or long-term treatment.
Women with a prior breast-cancer diagnosis were also excluded from HSDD trials. The guidance recommends caution for women with hormone-sensitive breast cancer. These gaps make individual medical history important to a qualified clinician’s assessment.
Reuters reported in September 2026 that there was no FDA-approved testosterone product for women in the United States. It also reported increasing off-label use for persistently low sexual desire. Growing use and regulatory approval are different facts, and neither substitutes for an individual assessment.
In separate September 2026 reporting about an FDA workshop, Reuters described experts drawing attention to unresolved long-term safety questions. Cardiovascular and breast-cancer concerns were among the issues discussed. That regulatory discussion concerned evidence gaps rather than a prediction about what would happen to any particular person receiving treatment.
For readers, the useful distinction is between availability and suitability. The fact that a treatment is being prescribed does not explain whether the evidence fits a person’s circumstances. That explanation belongs in the clinical conversation.
The most grounded response to a persistent and distressing change in desire is a careful clinical conversation, not an assumption of hormone deficiency. A useful organizing question is: What specific concern is this treatment intended to improve? That keeps attention on the person’s experience rather than on a broad promise about hormones.
Several questions can make the reasoning clearer:
These questions are not a test that readers must pass before seeking help. They are a way to understand why a treatment is being considered and what the decision involves. Personal choices about treatment belong with a qualified clinician who can assess the full situation.
The consensus describes care that may involve hormonal or nonhormonal treatment, psychotherapy or a combined approach. A careful assessment is therefore not merely a formality before a prescription. It helps establish which concern is being addressed and which options deserve consideration.
That approach fits a broader framework for sexual-health decisions as adulthood changes. The aim is neither to dismiss distress nor to turn every shift in desire into a hormone problem. It is to make the discussion specific enough that the evidence becomes useful.
A change in desire belongs to a person’s life, not simply to a number waiting to be corrected.
Testosterone evidence addresses a limited clinical question rather than every change in sexual function, and Sexential works within that boundary through calm sexual-wellbeing education. Its coverage brings hormones together with health and relationships for adults aged 35 to 65, helping readers put uncertainty about sexual function into context without turning general information into a personal prescription.
Follow Sexential for thoughtful guidance on desire, sexual function, hormones, confidence, relationships and intimacy. Explore new articles and evidence-aware resources for sexual wellbeing across adulthood.
A report on a student survey links attention with men’s sexual satisfaction. Here’s the evidence, its limits and the practical context for midlife.
A new report puts men’s midlife testosterone changes in context, with guidance on assessment, partner conversations and fertility considerations.
The Menopause Society’s 2026 program places lifestyle, sleep and sexual health together. Here is what the agenda and partner research actually report.
Explore practical resources on desire, function, hormones, confidence, intimacy and sexual wellbeing.
Read the Blog
